Heart study shows many suffer poor quality of lifeSeptember 15, 2009The world's largest quality of life study of chronic angina patients attending general practice clinics has revealed that almost one in three experience frequent chest pain, which affects their daily life. The collaborative project between the University of Adelaide and Servier Australia surveyed more than 2000 chronic angina patients throughout Australia and has been published today in the Archives of Internal Medicine. Lead author Associate Professor John Beltrame says the study showed that 29% of patients experienced angina chest pain at least once a week, despite contemporary treatments which include medications, balloon/stent treatments and bypass surgery. Angina is a tightness in the chest that typically occurs with exertion and is due to a narrowing of a coronary artery. It can lead to heart attacks. "More than 60% of patients with chronic angina reported that their angina limited their enjoyment of life," Associate Professor Beltrame says. "Although quality assurance programs of chronic angina patients examine how well weight, cholesterol and blood pressure are controlled, the one symptom that patients complain about - chest pain - has no defined benchmark." He says the findings show a new management strategy is required to optimise the treatment of angina and improve the quality of life for these patients. "This study provides the foundations for establishing such guidelines, allowing closer monitoring of angina control," Associate Professor Beltrame says. Associate Professor Beltrame is also a Consultant Cardiologist with the Queen Elizabeth Hospital and Lyell McEwin Hospital and a National Heart Foundation Research Fellow. The Head of the University of Adelaide's Discipline of General Practice, Professor Nigel Stocks, says the study's findings present a lot of challenges for general practitioners. "We know that with aggressive lifestyle modification and appropriate medical management, nearly 60% of patients with angina can be pain free after one year. This study highlights the importance of GPs closely monitoring their patients with chronic angina and encouraging them to report recurring chest pain," he says. The study was unconditionally funded by Servier Australia, a subsidiary of the leading French research-based pharmaceutical entity, specialising in ethical pharmaceuticals. The University of Adelaide |
|||||||||||||||||||||
| Related Angina Current Events and Angina News Articles Pivotal study for PSD502 -- the first potential treatment for premature ejaculation At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora" - AIM:PLE)., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE). Your Own Stem Cells Can Treat Heart Disease The largest national stem cell study for heart disease showed the first evidence that transplanting a potent form of adult stem cells into the heart muscle of subjects with severe angina results in less pain and an improved ability to walk. The transplant subjects also experienced fewer deaths than those who didn't receive stem cells. Elevated biomarkers lead to diminished quality of life in heart attack patients post-discharge Many heart attack patients have high levels of cardiac biomarkers in the blood for several months after leaving the hospital, with more shortness of breath and chest pain, according to a Henry Ford Hospital study. Angina in the legs? Time to alert patients and physicians Edmonton researchers recommend that people over age 40 be screened for peripheral artery disease (PAD), which puts people at high risk for serious medical complications including heart disease, stroke, and possible lower limb amputation. Coronary imaging techniques helps to identify plaques likely to cause heart attacks Late-breaking results from the PROSPECT clinical trial shed new light on the types of vulnerable plaque that are most likely to cause sudden, unexpected adverse cardiac events, and on the ability to identify them through imaging techniques before they occur. Endothelin-Related Drugs Benefit Patients With Pulmonary Hypertension Recent research to block the effects of endothelin, a powerful substance that constricts blood vessels and stimulates cell growth, has led to successful treatment of pulmonary arterial hypertension and provides hope for treating other chronic diseases. GERD negatively impacts sleep quality, results in considerable economic burden There has been much debate about the relationship between gastroesophageal reflux disease (GERD) and sleep. Results from the Kyoto heart study The KYOTO HEART Study, which took place in Japan between January 2004 and January 2009, shows that the addition of valsartan to conventional antihypertensive treatment to improve blood pressure control is associated with an improved cardiovascular outcome in Japanese hypertensive patients at high risk of CVD events. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes Data from a phase II trial of an investigational intravenous drug designed to block the formation of blood clots shows potential to reduce the risk of death, a second heart attack, or other coronary complications compared with the current standard of care in patients presenting with acute coronary syndromes (heart attacks or unstable angina). Surprising rate of recurring heart attacks, strokes globally Despite many medicines and other treatments for patients with vascular disease, a large international study shows these patients have a surprisingly high rate of recurring events such as strokes, heart attacks and hospitalizations as well as mortality. More Angina Current Events and Angina News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||